Overview

Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

The combination of taxanes, and especially docetaxel, with an anthracycline seems to be an important part of the chemotherapy regimens used in the adjuvant setting of patients with early-stage node-positive breast cancer patients. Whether sequential or concurrent administration of these drugs is preferable is not yet known, especially in patients with node-negative high risk tumors.

Phase:

Phase 3

Details

Lead Sponsor:

Hellenic Oncology Research Group

Collaborator:

University Hospital of Crete

Treatments:

Docetaxel
Epirubicin